Till Bruckner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Till Bruckner has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Ronak Borana
XLRI, Jamshedpur, Jharkhand, India
5 shared publications- Gustav Nilsonne
Karolinska Institutet
4 shared publications - Nicholas J. DeVito
University of Oxford
4 shared publications Aminul Schuster
University of Westminster, London
3 shared publicationsBelén Chavarría
National Autonomous University of Nicaragua-León, León, Nicaragua
3 shared publicationsCarolina Cruz
Universidad de Guadalajara, Guadalajara, Mexico
3 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 200
TrialScout links published results to trial registrations using a large language model
- 26 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 200
Open AccessTrialScout links published results to trial registrations using a large language model
- Open Access
Assessing Compliance with Reporting Requirements in European Phase II–IV Clinical Trials: A Cross-Sectional Observational Study
Objectives: To assess the availability of key clinical trial registration data and compliance with legal reporting requirements for all Phase 2-4 drug trials registered on the new European Clinical Trial Information System (CTIS) registry. This study is the first ever assessment of data quality and legal compliance with reporting requirements on CTIS. Design: Cross-sectional observational study of CTIS registry data combined with manual review of results documents. Setting: Cohort of all 7,547 Phase II-IV clinical trials registered on CTIS as of November 2025. Main outcome measures: Number and proportion of missing data points in CTIS registration data. Proportion of completed clinical trials that are compliant with regulatory reporting requirements. Results: Trial registration data quality was high overall with more than 99% of expected data present. Of 234 clinical trials legally required to report results, fewer than half (49.6%) fully reported results within the required timeframe, 20 trials (8.5%) fully reported results late, and 98 trials (41.9%) failed to fully report results. Legal compliance was similar for adult trials (79/158) and paediatric trials (37/76). Conclusions: Sponsor compliance with legal reporting requirements is weak. Current efforts by European regulators to monitor and enforce compliance appear to be insufficient. New results reporting functions currently being set up by trial registries worldwide will require quality assurance processes. Trial registration: Study protocol prospectively registered on OSF: https://osf.io/sn4j2/overview
Open AccessAssessing Compliance with Reporting Requirements in European Phase II–IV Clinical Trials: A Cross-Sectional Observational Study
Objectives: To assess the availability of key clinical trial registration data and compliance with legal reporting requirements for all Phase 2-4 drug trials registered on the new European Clinical Trial Information System (CTIS) registry. This study is the first ever assessment of data quality and legal compliance with reporting requirements on CTIS. Design: Cross-sectional observational study of CTIS registry data combined with manual review of results documents. Setting: Cohort of all 7,547 Phase II-IV clinical trials registered on CTIS as of November 2025. Main outcome measures: Number and proportion of missing data points in CTIS registration data. Proportion of completed clinical trials that are compliant with regulatory reporting requirements. Results: Trial registration data quality was high overall with more than 99% of expected data present. Of 234 clinical trials legally required to report results, fewer than half (49.6%) fully reported results within the required timeframe, 20 trials (8.5%) fully reported results late, and 98 trials (41.9%) failed to fully report results. Legal compliance was similar for adult trials (79/158) and paediatric trials (37/76). Conclusions: Sponsor compliance with legal reporting requirements is weak. Current efforts by European regulators to monitor and enforce compliance appear to be insufficient. New results reporting functions currently being set up by trial registries worldwide will require quality assurance processes. Trial registration: Study protocol prospectively registered on OSF: https://osf.io/sn4j2/overview
- Open Access
TrialScout links published results to trial registrations using a large language model
Background and Objective: Multiple stakeholders need to locate results of registered clinical trials but frequently struggle to find them. Summary results of clinical trials are often not published in trial registries, and publications containing trial results are often not explicitly linked to their respective trial registrations. Finding these results is important to researchers, systematic reviewers, research funders, regulators, clinical practitioners, and patients. Methods: We developed TrialScout, a computer program that uses a large language model to match clinical trials registered on ClinicalTrials.gov with corresponding result publications indexed in PubMed. TrialScout’s performance was evaluated through comparison to human-coded matches from previous studies of results reporting rates. Subsequently, TrialScout was applied to a random sample of 9,600 completed or terminated trials. Results: TrialScout had a sensitivity of 92.5% and a specificity of 81.2% compared to human coders. Manual review of 200 cases where TrialScout disagreed with human researchers showed that a majority (123/200, 61.5%, 95% CI, 54.4–68.3%) of disagreements were due to human errors. When used on 9,600 sampled trials in ClinicalTrials.gov , TrialScout found result publications for 6,110 (63.6%) of trials. Conclusions: TrialScout reliably located results of completed clinical trials. The tool offers benefits in terms of speed and efficiency. Estimating TrialScout’s accuracy is limited by the lack of a true gold standard. TrialScout can accelerate the process of locating trial results in the scientific literature and can assist in monitoring trial reporting practices. What is new: TrialScout matches published results to clinical trial registrations TrialScout uses a large language model to compare publications to registrations Accuracy rivals searching by human researchers Most disagreements between TrialScout and humans were due to human error TrialScout found published results for 63.6% of 9,600 trials from clinicaltrials.gov
Open AccessTrialScout links published results to trial registrations using a large language model
Background and Objective: Multiple stakeholders need to locate results of registered clinical trials but frequently struggle to find them. Summary results of clinical trials are often not published in trial registries, and publications containing trial results are often not explicitly linked to their respective trial registrations. Finding these results is important to researchers, systematic reviewers, research funders, regulators, clinical practitioners, and patients. Methods: We developed TrialScout, a computer program that uses a large language model to match clinical trials registered on ClinicalTrials.gov with corresponding result publications indexed in PubMed. TrialScout’s performance was evaluated through comparison to human-coded matches from previous studies of results reporting rates. Subsequently, TrialScout was applied to a random sample of 9,600 completed or terminated trials. Results: TrialScout had a sensitivity of 92.5% and a specificity of 81.2% compared to human coders. Manual review of 200 cases where TrialScout disagreed with human researchers showed that a majority (123/200, 61.5%, 95% CI, 54.4–68.3%) of disagreements were due to human errors. When used on 9,600 sampled trials in ClinicalTrials.gov , TrialScout found result publications for 6,110 (63.6%) of trials. Conclusions: TrialScout reliably located results of completed clinical trials. The tool offers benefits in terms of speed and efficiency. Estimating TrialScout’s accuracy is limited by the lack of a true gold standard. TrialScout can accelerate the process of locating trial results in the scientific literature and can assist in monitoring trial reporting practices. What is new: TrialScout matches published results to clinical trial registrations TrialScout uses a large language model to compare publications to registrations Accuracy rivals searching by human researchers Most disagreements between TrialScout and humans were due to human error TrialScout found published results for 63.6% of 9,600 trials from clinicaltrials.gov
- Open Access
- 5 March 2026
- Published by UiT The Arctic University of Norway in iC3 Report Series
- Vol. 2
Annual Report 2025
2025 marks iC3’s third year as a Research Council of Norway Centre of Excellence. Since its start-up in 2023, the Centre has grown into a dynamic and collaborative hub for polar cryospheric research, supporting groundbreaking science and fostering a stimulating research environment. iC3 scientists continue to contribute vital scientific knowledge on ice sheets, carbon cycles and ocean ecosystems through interdisciplinary collaboration across the entire ice-to-ocean continuum, via both field campaigns in Svalbard, Greenland, mainland Norway and Antarctica, and integration of observational science and modelling. Early career researchers remain central to iC3’s strategic vision and play a key role through their active commitment to both science and communication. Furthermore, iC3’s research infrastructure is expanding, with the PolarMAGIC lab now fully operational, and the PlasmaLab successfully funded and under development. Over the coming year, iC3 will continue its pursuit of high-impact science driven by important collaborations between UiT The Arctic University of Norway, the Norwegian Polar Institute, and NORCE, and supported by its vibrant research culture.
- 5 March 2026
- Published by UiT The Arctic University of Norway in iC3 Report Series
- Vol. 2
Open AccessAnnual Report 2025
2025 marks iC3’s third year as a Research Council of Norway Centre of Excellence. Since its start-up in 2023, the Centre has grown into a dynamic and collaborative hub for polar cryospheric research, supporting groundbreaking science and fostering a stimulating research environment. iC3 scientists continue to contribute vital scientific knowledge on ice sheets, carbon cycles and ocean ecosystems through interdisciplinary collaboration across the entire ice-to-ocean continuum, via both field campaigns in Svalbard, Greenland, mainland Norway and Antarctica, and integration of observational science and modelling. Early career researchers remain central to iC3’s strategic vision and play a key role through their active commitment to both science and communication. Furthermore, iC3’s research infrastructure is expanding, with the PolarMAGIC lab now fully operational, and the PlasmaLab successfully funded and under development. Over the coming year, iC3 will continue its pursuit of high-impact science driven by important collaborations between UiT The Arctic University of Norway, the Norwegian Polar Institute, and NORCE, and supported by its vibrant research culture.
- Open Access
- 16 April 2025
- Published by UiT The Arctic University of Norway in iC3 Report Series
- Vol. 1
Annual Report 2024
Since the establishment of iC3 in July 2023, we can reflect on an exciting period marked by increasing activity within the Centre. During this time of significant growth, it has been both inspiring and motivating to see the development of a supportive and stimulating research culture among our diverse team of scientists and across iC3´s partnership of UiT The Arctic University of Norway, the Norwegian Polar Institute and NORCE.
- 16 April 2025
- Published by UiT The Arctic University of Norway in iC3 Report Series
- Vol. 1
Open AccessAnnual Report 2024
Since the establishment of iC3 in July 2023, we can reflect on an exciting period marked by increasing activity within the Centre. During this time of significant growth, it has been both inspiring and motivating to see the development of a supportive and stimulating research culture among our diverse team of scientists and across iC3´s partnership of UiT The Arctic University of Norway, the Norwegian Polar Institute and NORCE.
- Open Access
- 1 May 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 431
Regulatory gaps and research waste in clinical trials involving women with metastatic breast cancer in Germany
Background Non-publication, incomplete publication and excessively slow publication of clinical trial outcomes contribute to research waste and can harm patients. While research waste in German academic trials is well documented, research waste in Germany related to a specific disease area across non-commercial and commercial sponsors has not previously been assessed. Methods In this cohort study, we used public records from three clinical trial registries to identify 70 completed or terminated clinical trials involving women with metastatic breast cancer with trial sites in Germany. We then searched registries and the literature for trial outcomes and contacted sponsors about unreported studies. Results We found that 66/70 trials (94.3%) had made their results public. Only 13/70 (18.6%) trials had reported results within one year of completion as recommended by the World Health Organisation (WHO). The outcomes of 4/70 trials (5.7%) had not been made public at all, but only one of those trials had recruited a significant number of patients. Conclusions Discussions about research waste in clinical trials commonly focus on weakly designed or unreported trials. We believe that late reporting of results is another important form of research waste. In addition, a discussion regarding the appropriate ethical and legal rules for reporting the results of terminated trials might add value. German legislation now requires sponsors to upload the results of some clinical trials onto a trial registry within one year of trial completion, but these laws only cover around half of all trials. Our findings highlight the potential benefits of extending the scope of national legislation to cover all interventional clinical trials involving German patients.
- 1 May 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 431
Open AccessRegulatory gaps and research waste in clinical trials involving women with metastatic breast cancer in Germany
Background Non-publication, incomplete publication and excessively slow publication of clinical trial outcomes contribute to research waste and can harm patients. While research waste in German academic trials is well documented, research waste in Germany related to a specific disease area across non-commercial and commercial sponsors has not previously been assessed. Methods In this cohort study, we used public records from three clinical trial registries to identify 70 completed or terminated clinical trials involving women with metastatic breast cancer with trial sites in Germany. We then searched registries and the literature for trial outcomes and contacted sponsors about unreported studies. Results We found that 66/70 trials (94.3%) had made their results public. Only 13/70 (18.6%) trials had reported results within one year of completion as recommended by the World Health Organisation (WHO). The outcomes of 4/70 trials (5.7%) had not been made public at all, but only one of those trials had recruited a significant number of patients. Conclusions Discussions about research waste in clinical trials commonly focus on weakly designed or unreported trials. We believe that late reporting of results is another important form of research waste. In addition, a discussion regarding the appropriate ethical and legal rules for reporting the results of terminated trials might add value. German legislation now requires sponsors to upload the results of some clinical trials onto a trial registry within one year of trial completion, but these laws only cover around half of all trials. Our findings highlight the potential benefits of extending the scope of national legislation to cover all interventional clinical trials involving German patients.
- 17 April 2024
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 29 (6) , 426-427
Major UK non-commercial sponsors’ efforts to reduce research waste: a mixed-methods study
- 17 April 2024
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 29 (6) , 426-427
Major UK non-commercial sponsors’ efforts to reduce research waste: a mixed-methods study
- Open Access
Publication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies: An observational cohort study
Transparency shortcomings can undermine confidence in the safety and efficacy of vaccines. This study assesses the publication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies that received a World Health Organization Emergency Use Listing (EUL) and have been marketed globally. We searched trial registries and the scientific literature to assess the completion status of those 71 trials, and to determine whether the outcomes of completed trials have been made publicly available. The 71 trials in our cohort were initiated by sponsors headquartered in 17 different countries and aimed to enrol a total of 313,750 participants from across 27 countries. Out of those 71 trials, 49 trials (69%) had verifiably been concluded. We were unable to determine the completion status of the remaining 22 trials (31%) with certainty. Depending on whether those 22 trials were assumed to have been concluded or not, we found that between 13 completed trials (27%) and 35 completed trials (49%) remained unreported. At least 9 trials (13% of the total) had not made their results public more than one year post completion. According to registry data, between 36,498 people (12% of participants across all trials) and 89,224 people (28%) had participated in trials that had been concluded and whose outcomes remained unreported. There were no tabular summary results available on trial registries for any of the trials. Our findings suggest that there are significant gaps in clinical trial governance, especially in countries that have only recently emerged as significant players in biomedical research. Maintaining global progress in clinical trial reporting will require legislators and regulators to adopt and effectively enforce clinical trial reporting requirements that reflect WHO best practices. The global clinical trial registry infrastructure needs to be strengthened so that users can reliably determine whether studies have been withdrawn, are still ongoing, or have been concluded. Key messages: What is already known on this topic: The results of many clinical trials are only made public partially, after long delays, or not at all. Such disclosure gaps can make it difficult to assess the benefits and harms of treatments, and can undermine public trust in health interventions, including vaccines. In North America and Europe, disclosure has significantly improved in recent years. What this study adds: Previous research in this field has overwhelmingly focused on clinical trials run by sponsors in North America and Europe that usually involved patients in these regions. Our study provides a global perspective on the problem, using a cohort of trials with high salience for global public health. More than 1.3 billion doses of 3 COVID-19 vaccines originally developed in China have been exported to dozens of countries worldwide. We assessed the publication status and disclosure gaps of 71 clinical trials of these vaccines. We found widespread research activity in newly emerging hubs of biomedical innovation. In total, sponsors from 17 different countries and participants from 27 countries were involved in relevant trials. None of the concluded trials had reported outcomes in line with global best practice standards set out by the World Health Organisation. How this study might affect research, practice or policy: Clinical trial activity is increasingly becoming global. Our research points to significant gaps in clinical trial governance in many emerging hubs of biomedical innovation. Legislators and regulators in these countries should ensure that all clinical trial results are rapidly made public in line with World Health Organisation best practices to prevent the growth of gaps in the global medical evidence base. In addition, there is an urgent need to strengthen the global clinical trial registry infrastructure.
Open AccessPublication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies: An observational cohort study
Transparency shortcomings can undermine confidence in the safety and efficacy of vaccines. This study assesses the publication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies that received a World Health Organization Emergency Use Listing (EUL) and have been marketed globally. We searched trial registries and the scientific literature to assess the completion status of those 71 trials, and to determine whether the outcomes of completed trials have been made publicly available. The 71 trials in our cohort were initiated by sponsors headquartered in 17 different countries and aimed to enrol a total of 313,750 participants from across 27 countries. Out of those 71 trials, 49 trials (69%) had verifiably been concluded. We were unable to determine the completion status of the remaining 22 trials (31%) with certainty. Depending on whether those 22 trials were assumed to have been concluded or not, we found that between 13 completed trials (27%) and 35 completed trials (49%) remained unreported. At least 9 trials (13% of the total) had not made their results public more than one year post completion. According to registry data, between 36,498 people (12% of participants across all trials) and 89,224 people (28%) had participated in trials that had been concluded and whose outcomes remained unreported. There were no tabular summary results available on trial registries for any of the trials. Our findings suggest that there are significant gaps in clinical trial governance, especially in countries that have only recently emerged as significant players in biomedical research. Maintaining global progress in clinical trial reporting will require legislators and regulators to adopt and effectively enforce clinical trial reporting requirements that reflect WHO best practices. The global clinical trial registry infrastructure needs to be strengthened so that users can reliably determine whether studies have been withdrawn, are still ongoing, or have been concluded. Key messages: What is already known on this topic: The results of many clinical trials are only made public partially, after long delays, or not at all. Such disclosure gaps can make it difficult to assess the benefits and harms of treatments, and can undermine public trust in health interventions, including vaccines. In North America and Europe, disclosure has significantly improved in recent years. What this study adds: Previous research in this field has overwhelmingly focused on clinical trials run by sponsors in North America and Europe that usually involved patients in these regions. Our study provides a global perspective on the problem, using a cohort of trials with high salience for global public health. More than 1.3 billion doses of 3 COVID-19 vaccines originally developed in China have been exported to dozens of countries worldwide. We assessed the publication status and disclosure gaps of 71 clinical trials of these vaccines. We found widespread research activity in newly emerging hubs of biomedical innovation. In total, sponsors from 17 different countries and participants from 27 countries were involved in relevant trials. None of the concluded trials had reported outcomes in line with global best practice standards set out by the World Health Organisation. How this study might affect research, practice or policy: Clinical trial activity is increasingly becoming global. Our research points to significant gaps in clinical trial governance in many emerging hubs of biomedical innovation. Legislators and regulators in these countries should ensure that all clinical trial results are rapidly made public in line with World Health Organisation best practices to prevent the growth of gaps in the global medical evidence base. In addition, there is an urgent need to strengthen the global clinical trial registry infrastructure.
- Open Access
Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed
Objective To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. Study Design and Setting In this cross-sectional study, we included trials (regardless of intervention) registered in the EU Clinical Trials Registry and/or ClinicalTrials.gov, completed 2016-2019, and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries, and conducted systematic manual searches for results publications (e.g., journal articles, preprints). We present proportions with 95% confidence intervals (CI), and medians with interquartile range (IQR). Protocol: https://osf.io/wua3r Results Among 2,113 included clinical trials, 1,638 (77.5%, 95%CI 75.9-79.2%) reported any results during our follow-up; 1,092 (51.7%, 95%CI 49.5-53.8%) reported any results within 2 years of the global completion date; and 42 (2%, 95%CI 1.5-2.7%) posted summary results in the registry within 1 year. Median time from global completion date to results reporting was 698 days (IQR 1,123). 856/1,681 (50.9%) of ClinicalTrials.gov-registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions. Conclusion Missing and delayed results reporting of academically-led clinical trials is a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policy makers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost. What is new? - Many Nordic registered clinical trials were reported late or not at all. - Almost one in four trials remained unreported at the end of our search period. - About half of registered trials had reported results two years after completion. - Only 2% of trials posted summary results in the registry one year after completion. - Concerted action is needed to improve reporting of Nordic clinical trials.
Open AccessResults reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed
Objective To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. Study Design and Setting In this cross-sectional study, we included trials (regardless of intervention) registered in the EU Clinical Trials Registry and/or ClinicalTrials.gov, completed 2016-2019, and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries, and conducted systematic manual searches for results publications (e.g., journal articles, preprints). We present proportions with 95% confidence intervals (CI), and medians with interquartile range (IQR). Protocol: https://osf.io/wua3r Results Among 2,113 included clinical trials, 1,638 (77.5%, 95%CI 75.9-79.2%) reported any results during our follow-up; 1,092 (51.7%, 95%CI 49.5-53.8%) reported any results within 2 years of the global completion date; and 42 (2%, 95%CI 1.5-2.7%) posted summary results in the registry within 1 year. Median time from global completion date to results reporting was 698 days (IQR 1,123). 856/1,681 (50.9%) of ClinicalTrials.gov-registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions. Conclusion Missing and delayed results reporting of academically-led clinical trials is a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policy makers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost. What is new? - Many Nordic registered clinical trials were reported late or not at all. - Almost one in four trials remained unreported at the end of our search period. - About half of registered trials had reported results two years after completion. - Only 2% of trials posted summary results in the registry one year after completion. - Concerted action is needed to improve reporting of Nordic clinical trials.
- Open Access
- 12 January 2024
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
- Vol. 9 (1) , 75-76
When lawyers pay scientists to join a billion-dollar fight over medical evidence
BOOK R ...
- 12 January 2024
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
- Vol. 9 (1) , 75-76
Open AccessWhen lawyers pay scientists to join a billion-dollar fight over medical evidence
BOOK R ...